BOCA RATON, FL -- (Marketwire) -- 03/18/09 -- Vicor Technologies, Inc. (OTCBB: VCRT) today announced that it has entered into a collaborative research agreement with the University of Rochester and the Catalan Institute of Cardiovascular Sciences in Barcelona to study sudden cardiac death. Vicor Technologies is a development-stage biotechnology company focused on the commercialization of innovative non-invasive diagnostics for sudden cardiac death and trauma using its patented, proprietary PD2i algorithm.

According to the agreement, titled, "Prognostic Significance of Point Correlation Dimension Algorithm (PD2i) in Chronic Heart Failure," Vicor's PD2i Cardiac Analyzer will be used by University of Rochester personnel to identify which of the 651 congestive heart failure patients who participated in the Merte Subita en Insufficiencia Cardiaca (MUSIC) Trial suffered sudden cardiac death. During the average 44 months MUSIC Trial participants were followed, 52 died from sudden cardiac death. Vicor expects to have the results of its MUSIC Trial data analysis during the second quarter of 2009.

"We are extremely excited to be able to have this opportunity to analyze the MUSIC Trial patient data with our PD2i Cardiac Analyzer," stated David H. Fater, Vicor President and CEO. "An archive of analyzable data such as this -- which is unusual to obtain -- is a major accomplishment, as it enables us to quickly and cost-effectively produce a statistically significant clinical dataset," Mr. Fater concluded.

About Vicor Technologies, Inc.

Vicor Technologies is a development-stage biotechnology company creating innovative non-invasive diagnostics employing its patented, proprietary point correlation dimension algorithm (PD2i.) The PD2i is a deterministic, non-linear measure that analyzes electrophysiological potentials to predict future pathological events with a high degree of accuracy in target populations.

Vicor currently has three products employing the PD2i algorithm. The PD2i Analyzer, now in commercialization, measures heart rate variability. The PD2i VS (Vital Sign), in clinical trials under a collaborative effort with the U.S. Army Institute for Surgical Research (http://www.usaisr.amedd.army.mil/), risk stratifies combat and civilian trauma victims. The PD2i CA (Cardiac Analyzer), currently involved in multiple clinical trials, identifies patients at risk of suffering sudden cardiac death.

Vicor anticipates additional applications employing the PD2i to enable early detection and risk stratification for a variety of other disorders and diseases.